FTH Valuation

Faeth Therapeutics, Inc (FTH) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of --. The fair price of Faeth Therapeutics, Inc (FTH) is between to according to relative valuation method.

FTH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Faeth Therapeutics, Inc (FTH) is between to according to relative valuation method.

The average P/S ratio for FTH's competitors is 21.87, providing a benchmark for relative valuation. Faeth Therapeutics, Inc Corp (FTH) exhibits a P/S ratio of --, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

As of Jul 05 2026, Faeth Therapeutics, Inc (FTH) has a P/B ratio of 3.09. This indicates that the market values FTH at 3.09 times its book value.

As of Jul 05 2026, Faeth Therapeutics, Inc (FTH) has a FCF Yield of -4.08%. This means that for every dollar of Faeth Therapeutics, Inc's market capitalization, the company generates -4.08 cents in free cash flow.

As of Jul 05 2026, Faeth Therapeutics, Inc (FTH) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Faeth Therapeutics, Inc's expected earnings over the next 12 months.

As of Jul 05 2026, Faeth Therapeutics, Inc (FTH) has a Forward P/S ratio of 0.00. This means the market is valuing FTH at $0.00 for every dollar of expected revenue over the next 12 months.